middle.news
Dimerix Secures Fifth Licensing Deal and Expands Pipeline with DMX-652 Acquisition
8:49am on Thursday 30th of July, 2026 AEST
•
Biotechnology
Read Story
Dimerix Secures Fifth Licensing Deal and Expands Pipeline with DMX-652 Acquisition
8:49am on Thursday 30th of July, 2026 AEST
Key Points
Fifth licensing deal with Everest Medicines worth up to A$481 million plus royalties
Aggregate licensing milestone potential rises to approximately A$1.9 billion
ACTION3 Phase 3 trial for DMX-200 remains over 90% statistically powered
Acquisition of Phase 2-ready renal asset DMX-652 expands pipeline
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE